BIOA BioAge Labs, Inc: Price-to-Projected Revenue Ratio

BioAge Labs, Inc. - graphic logo of issuer BIOA

The lack of profitability and reliance on venture capital create risks, yet the forward P/S of BioAge Labs, Inc. (BIOA) illustrates market optimism. The value 30.00 shows the level of this metric. Confidence is fueled by the success of azelaprag in combating obesity and strategic alliances to study aging processes, which opens a path for BioAge Labs, Inc. (BIOA) toward large-scale partnerships with pharma behemoths.

BioAge - BIOA Market Cap to Expected Sales Ratio (period 05/08/2025 - 11/13/2026)

Summary analytical data breakdowns for BioAge Labs, Inc (BIOA)

- market price and analyst price targets:
Price Chart BioAge|BIOA - Average Forecast Price
- company stock capitalization data:
Market Value BioAge Labs, Inc|BIOA - Total Company Value
- book value of equity indicators:
Book Value per Share BioAge Labs, Inc.|BIOA - Book Valuation of Business|Market Value to Book Value Ratio bioagelabs.com|BIOA - Company Total Asset Base
- business debt structure and liquidity details:
Debt to Equity BioAge Labs, Inc.|BIOA - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital BioAge Labs, Inc.|BIOA - Company Debts|Debts to Book Capitalization BioAge Labs, Inc|BIOA - Long-Term Debt Volume|Company Short-Term Debt BioAge Labs, Inc.|Quick Ratio bioagelabs.com
- financial results and valuation multiples details:
BIOA - Net Profit|Projected Future Earnings BioAge Labs, Inc.|BIOA - Market Cap to Net Income Ratio|Forward P/E Multiple BioAge Labs Inc.|BIOA - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio BioAge Labs, Inc|BIOA - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months BioAge Labs, Inc.|BIOA - Earnings per share for the last twelve months|Quarterly EPS earnings growth bioagelabs.com|BIOA - Earnings growth in current year|Earnings growth forecast for next year BioAge Labs, Inc.
- sales volume and revenue indicators:
BIOA - Company Revenue|Company Projected Revenue BioAge|BIOA - Price-to-Revenue Coefficient|Forward Price-to-Revenue Multiple BioAge Labs, Inc
Summary company analytics:BioAge BIOA
Original product of BioAge Labs, Inc

To minimize investment risks, it is critical to track the dynamics of market expectations regarding the future revenue of BioAge Labs, Inc. (BIOA) within the longevity medicine sector. An analysis of the projected P/S multiple allows for an assessment of the market's willingness to pay a premium for AI-driven metabolic analysis technologies by comparing current capitalization with projected earnings from the development of innovative drugs.

Analysis of competing companies

Price-to-Projected Revenue Ratio Ascendis Pharma ASND|Madrigal Pharmaceuticals Inc (MDGL) - Market Cap to Future Revenue Ratio|CORT - Price-to-Projected Revenue Ratio|RYTM: Price-to-Projected Revenue Ratio|AKRO: Forward P/S Multiple|MTSR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio MoonLake|Crinetics Pharmaceuticals, Inc. (CRNX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio NewAmsterdam Pharma N.V. (NAMS)|Forward Price-to-Revenue Multiple Soleno Therapeutics Corp SLNO|Forward P/S Multiple FOLD (Amicus Therapeutics)|89bio.com - Price-to-Projected Revenue Ratio|Agios Pharmaceuticals, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Structure Therapeutics Inc GPCR|MiMedx Group (MDXG) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Rezolute Bio (RZLT)|LXRX (Lexicon Pharmaceuticals) - Forward P/S Multiple|Forward P/S Multiple mbxbio.com|Forward P/S Multiple ALT|Aardvark Therapeutics Inc. (AARD) - Projected Price to Revenue|Forward P/S Multiple SGMT (Sagimet)|Biomea Fusion Corp (BMEA) - Market Cap to Future Revenue Ratio|QNCX: Forward Price-to-Revenue Multiple|Forward Price to Sales GUTS (fractyl.com)|vtvtherapeutics.com (VTVT) - Price-to-Projected Revenue Ratio|ATPC (Agape ATP) - Price-to-Projected Revenue Ratio|PLUR (Pluristem Therapeutics) - Forward P/S Multiple|Forward P/S Multiple Synlogic Corp|Forward P/S Multiple LPCN|Price-to-Projected Revenue Ratio MTNB (matinasbiopharma.com)|Price-to-Projected Revenue Ratio Spruce Biosciences, Inc. SPRB|Market Cap to Expected Sales Ratio Galecto Inc (GLTO)|CTCX: Forward Price-to-Revenue Multiple|Forward Price to Sales LUMO (Lumos Therapeutics)|ONVO: Forward P/S Multiple|RDUS - Market Cap to Expected Sales Ratio